Condition: Stargardt Disease · Sponsor: Alkeus Pharmaceuticals, Inc.
This study evaluates the efficacy and safety of investigational study drug ALK-001 in participants 8 to 45 years of age, inclusive, with symptoms and signs of autosomal recessive Stargardt disease (STGD)
This description comes directly from the study's public registry record.
For trial questions: trials@alkeuspharma.com or 877-255-7476 · 877-255-7476 · trials@alkeuspharma.com
Always discuss trial participation with your own doctor first.
| Associated Retina Consultants | Phoenix, Arizona, United States | Recruiting |
| Vitreo Retinal Associates | Gainesville, Florida, United States | Recruiting |
| Erie Retina Research | Erie, Pennsylvania, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
| Star Retina | Fort Worth, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07419334